Addition of Hypofractionated High Dose Radiation in Oligometastatic Disease

Addition of Hypofractionated High Dose Radiation in Oligometastatic Disease is a phase 3, randomised interventional study registered as NCT06141070 by Vastra Gotaland Region, with a registry enrolment figure of 240 participants, started 2023-12-01 and due to reach its primary completion in 2028-12-01. Interventions recorded: Standard systemic therapy + radiotherapy; Standard systemic therapy. Conditions listed: Non Small Cell Lung Cancer. Primary outcome: Overall survival (OS). Lung eligibility wording from the registry: "* Histological or cytological diagnosis of NSCLC". Sites: Sweden. No results are recorded here; the registry entry is the source.